Loqus23 Therapeutics Exits Stealth With £11.5 Million Seed Financing From The Dementia Discovery Fund And Novartis Venture Fund
Nov 23, 2021•over 3 years ago
Amount Raised
£11.5 Million
Round Type
seed
Description
LoQus23 Therapeutics Ltd. ('LoQus23'), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington's and other triplet repeat diseases (TRDs), announces the successful closing of its £7 million extended seed round. LoQus23 secured the financing from Novartis Venture Fund (NVF) and its founding investor the Dementia Discovery Fund (DDF). This round follows an initial £4.5 million seed investment by the DDF in 2019.
FundzWatch™ Score
76
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech